CD274 and neoplasm: Since PD1/PD-L1 blockade therapy is a widely used ICB therapy, and the tumor proportion score (TPS) of PD-L1 has been used to stratify potential responders for this therapy [23, 24], we tested this scenario by overexpressing PD-L1 in tumor cells.